Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDI6469 + rituximab
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
MEDI6469 + rituximab is a combination of two monoclonal antibodies. Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen on B cells, leading to their depletion through mechanisms such as complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. It is used in the treatment of various B-cell malignancies (such as non-Hodgkin lymphoma and chronic lymphocytic leukemia) and autoimmune diseases (including rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris)[1][2][6][8]. MEDI6469 is an investigational anti-OX40 monoclonal antibody designed to stimulate T-cell activation by targeting the OX40 receptor (CD134), which plays a role in immune modulation. The combination aims to enhance anti-tumor immune responses by depleting B cells with rituximab while activating T cells with MEDI6469.
- Other names
- none
02
Targets
CD20 (B-lymphocyte antigen CD20)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on MEDI6469 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDI6469 + rituximab.